Denali Therapeutics (DNLI) Accumulated Expenses (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Accumulated Expenses data on file, last reported at $69.8 million in Q1 2026.

• Quarterly Accumulated Expenses rose 848.82% year-over-year to $69.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $69.8 million (up 848.82% YoY) and the FY2025 annual result came in at $97.8 million, up 7.44% from the prior year.
• Accumulated Expenses slipped to $69.8 million in Q1 2026 per DNLI's latest filing, from $97.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $97.8 million in Q4 2025 and bottomed at $4.8 million in Q3 2024.
• The 5-year median for Accumulated Expenses is $10.3 million (2023), against an average of $29.4 million.
• The widest annual swing landed in 2024, when Accumulated Expenses slumped 70.45%; it then soared 848.82% in 2026.
• Tracing DNLI's Accumulated Expenses over 5 years: stood at $66.7 million in 2022, then climbed by 2.71% to $68.5 million in 2023, then soared by 32.95% to $91.1 million in 2024, then rose by 7.44% to $97.8 million in 2025, then retreated by 28.69% to $69.8 million in 2026.
• Per Business Quant, the three latest DNLI Accumulated Expenses figures stand at $69.8 million (Q1 2026), $97.8 million (Q4 2025), and $4.9 million (Q3 2025).

Peer Comparison